Good call Fangk, point taken. A loss of NZ$1-3M NZ with cash...

Good call Fangk, point taken.

A loss of NZ$1-3M NZ with cash reserves of NZ$30M is really not significant (in my view) with a 80%+ GM. In particular when they are spending so much on Selling and R&D which is more than the GM (extract below) resulting in negative earnings. So, question is will Sales hold up if they had less sales force or will they acheive more $/head sales with existing team with the same / new products? That would definitely turn the company profitable.
Besides that, I can't really find any reasons for negativity. Bit stumped on the price action for a long period of time now.
I dont really understand the BOT's and technicals but all I can see the volume / trade is very small and the company valuation is getting hammered as a result. And no broker / small-micro cap fund managerseems to cover this stock of recent times. Still buying but I am wondering what I am missing. Hmmmm.....

Sept 23 report
Normalised operating expenses
Selling and administrative expenses of NZ$27.5 million for the half-year were up 38%, compared to
H1 FY23 (NZ$19.9 million). On a constant currency basis, selling and administrative expenses were
up 36%, primarily reflecting increases to sales team headcount, increases in variable sales
compensation and increased clinical development activities.
Research and development expenses for the half-year of NZ$5.1 million were down 15%, compared
to H1 FY23, primarily reflecting the capitalisation of NZ$0.6 million in research in development costs
during H1 FY24 (H1 FY23 NZ$nil).